CREDELIO PLUS DIN 02525712

Status: Marketed

Holder: ELANCO CANADA LIMITED

Health Canada record

Active ingredient(s)	MILBEMYCIN OXIME 33.75 MG; LOTILANER 900 MG
Dosage form	Tablet (Chewable)
Route	Oral
Schedule	PRESCRIPTION
Class	Veterinary
ATC
Original market date	04-Aug-2022
Current status date	04-Aug-2022
Source	Health Canada DPD

Establishment licence of the holder

Elanco Canada Limited — licence 102236, currently licensed, last inspection rating C (2022-08-03).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing MILBEMYCIN OXIME

DIN	Product	Company	Form	Strength	Status
02525674	CREDELIO PLUS	ELANCO CANADA LIMITED	Tablet (Chewable)	MILBEMYCIN OXIME 2.11 MG; LOTILANER 56.25 MG	Marketed
02525704	CREDELIO PLUS	ELANCO CANADA LIMITED	Tablet (Chewable)	MILBEMYCIN OXIME 16.88 MG; LOTILANER 450 MG	Marketed
02525690	CREDELIO PLUS	ELANCO CANADA LIMITED	Tablet (Chewable)	MILBEMYCIN OXIME 8.44 MG; LOTILANER 225 MG	Marketed
02525682	CREDELIO PLUS	ELANCO CANADA LIMITED	Tablet (Chewable)	MILBEMYCIN OXIME 4.22 MG; LOTILANER 112.5 MG	Marketed
02141426	INTERCEPTOR FLAVOR TABS	ELANCO CANADA LIMITED	Tablet	MILBEMYCIN OXIME 5.75 MG	Marketed
02141396	INTERCEPTOR FLAVOR TABS	ELANCO CANADA LIMITED	Tablet	MILBEMYCIN OXIME 23 MG	Marketed
02141418	INTERCEPTOR FLAVOR TABS	ELANCO CANADA LIMITED	Tablet	MILBEMYCIN OXIME 11.5 MG	Marketed
02141434	INTERCEPTOR FLAVOR TABS	ELANCO CANADA LIMITED	Tablet	MILBEMYCIN OXIME 2.3 MG	Marketed
02468379	INTERCEPTOR PLUS	ELANCO CANADA LIMITED	Tablet	MILBEMYCIN OXIME 23 MG; PRAZIQUANTEL 228 MG	Marketed
02468344	INTERCEPTOR PLUS	ELANCO CANADA LIMITED	Tablet	MILBEMYCIN OXIME 2.3 MG; PRAZIQUANTEL 22.8 MG	Marketed
02468352	INTERCEPTOR PLUS	ELANCO CANADA LIMITED	Tablet	MILBEMYCIN OXIME 5.75 MG; PRAZIQUANTEL 57 MG	Marketed
02468360	INTERCEPTOR PLUS	ELANCO CANADA LIMITED	Tablet	MILBEMYCIN OXIME 11.5 MG; PRAZIQUANTEL 114 MG	Marketed
02556162	MILBEGUARD DUO	CEVA ANIMAL HEALTH INC	Tablet	MILBEMYCIN OXIME 16 MG; PRAZIQUANTEL 40 MG	Approved
02556154	MILBEGUARD DUO	CEVA ANIMAL HEALTH INC	Tablet	MILBEMYCIN OXIME 4 MG; PRAZIQUANTEL 10 MG	Approved
02291959	MILBEMAX	ELANCO CANADA LIMITED	Tablet	MILBEMYCIN OXIME 16 MG; PRAZIQUANTEL 40 MG	Marketed
02291940	MILBEMAX	ELANCO CANADA LIMITED	Tablet	MILBEMYCIN OXIME 4 MG; PRAZIQUANTEL 10 MG	Marketed
02016729	INTERCEPTOR CHEWABLE TAB 23MG	CIBA-GEIGY CANADA LTD, ANIMAL HEALTH DIVISION	Tablet	MILBEMYCIN OXIME 23 MG	Cancelled Post Market
00846449	INTERCEPTOR TAB 11.5MG	CIBA-GEIGY CANADA LTD, ANIMAL HEALTH DIVISION	Tablet	MILBEMYCIN OXIME 11.5 MG	Cancelled Post Market
00846422	INTERCEPTOR TAB 2.3MG	CIBA-GEIGY CANADA LTD, ANIMAL HEALTH DIVISION	Tablet	MILBEMYCIN OXIME 2.3 MG	Cancelled Post Market
00846457	INTERCEPTOR TAB 23MG	CIBA-GEIGY CANADA LTD, ANIMAL HEALTH DIVISION	Tablet	MILBEMYCIN OXIME 23 MG	Cancelled Post Market
00846430	INTERCEPTOR TAB 5.75MG	CIBA-GEIGY CANADA LTD, ANIMAL HEALTH DIVISION	Tablet	MILBEMYCIN OXIME 5.75 MG	Cancelled Post Market
02246889	MILBEMITE	ELANCO CANADA LIMITED	Solution	MILBEMYCIN OXIME 0.1 %	Cancelled Post Market
02238148	SENTINEL FLAVOR TABS	ELANCO CANADA LIMITED	Tablet	MILBEMYCIN OXIME 11.5 MG; LUFENURON 230 MG	Cancelled Post Market
02238147	SENTINEL FLAVOR TABS	ELANCO CANADA LIMITED	Tablet	MILBEMYCIN OXIME 23 MG; LUFENURON 460 MG	Cancelled Post Market
02238149	SENTINEL FLAVOR TABS	ELANCO CANADA LIMITED	Tablet	MILBEMYCIN OXIME 5.75 MG; LUFENURON 115 MG	Cancelled Post Market
02238150	SENTINEL FLAVOR TABS	ELANCO CANADA LIMITED	Tablet	MILBEMYCIN OXIME 2.3 MG; LUFENURON 46 MG	Cancelled Post Market
02229547	SENTINEL TABLETS 115/5.75	NOVARTIS ANIMAL HEALTH CANADA INC	Tablet	MILBEMYCIN OXIME 5.75 MG; LUFENURON 115 MG	Cancelled Post Market
02229548	SENTINEL TABLETS 230/11.5	NOVARTIS ANIMAL HEALTH CANADA INC	Tablet	MILBEMYCIN OXIME 11.5 MG; LUFENURON 230 MG	Cancelled Post Market
02229551	SENTINEL TABLETS 46/2.3	NOVARTIS ANIMAL HEALTH CANADA INC	Tablet	MILBEMYCIN OXIME 2.3 MG; LUFENURON 46 MG	Cancelled Post Market
02229549	SENTINEL TABLETS 460/23	NOVARTIS ANIMAL HEALTH CANADA INC	Tablet	MILBEMYCIN OXIME 23 MG; LUFENURON 460 MG	Cancelled Post Market

Notices of Compliance

NOC	Date	Submission	Reason
37280	2026-04-09	Supplement to a New Drug Submission (SNDS)	Additional Indication (treatment of sarcoptic mange caused by Sarcoptes scabiei)
36625	2025-12-24	Supplement to a New Drug Submission (SNDS)	Additional claim for treatment of demodicosis in dogs
27711	2022-03-04	New Drug Submission (NDS)

Request a quote for CREDELIO PLUS

How to read a Canadian DIN record